Browsing Other Campus Research by Author "Naqash, Abdul Rafeh"
-
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
Naqash, Abdul Rafeh; File, Danielle M.; Ziemer, Carolyn M.; Whang, Young E.; Landman, Paula; Googe, Paul B.; Collichio, Frances A. (2018-12-16)Background With the advent of immune-checkpoint inhibitors and targeted treatments (TT), there have been unprecedented response rates and survival in advanced melanoma, but the optimal sequencing of these two treatments ... -
Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
Macherla, Shravanti; Laks, Shachar; Naqash, Abdul Rafeh; Bulumulle, Anushi; Zervos, Emmanuel; Muzaffar, Mahvish (2018-11-07)Immune checkpoint blockade (ICB) with programmed cell death protein-1(PD-1)/programmed death ligand -1(PD-L1) antibodies has revolutionized the management of several cancers, especially non-small cell lung cancer, melanoma, ... -
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
Naqash, Abdul Rafeh; Appah, Ebenezer; Yang, Li V.; Muzaffar, Mahvish; Marie, Mona A.; Mccallen, Justin D.; Macherla, Shravanti; Liles, Darla; Walker, Paul R. (2019-07-05)Background Compared to conventional chemotherapy, Immune checkpoint inhibitors (ICI) are known to have a distinct toxicity profile commonly identified as immune-related adverse events (irAEs). These irAEs that are believed ...